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18F-FLT) is a tracer used to assess cell proliferation in vivo. The aim of the
study was to use
18F-FLT positron emission tomography (PET) to study treatment responses to a new anti-cancer
compound. To do so, we studied early anti-proliferative effects of the experimental chemotherapy Top216 non-invasively by
PET.
Methodology/Principal Findings: In vivo uptake of
18F-FLT in human ovary cancer xenografts in mice (A2780) was studied
at various time points after Top216 treatment (50 mg/kg i.v. at 0 and 48 hours) was initiated. Baseline
18F-FLT scans were
made before either Top216 (n=7–10) or vehicle (n=5–7) was injected and repeated after 2 and 6 hours and 1 and 5 days of
treatment. A parallel study was made with 29-deoxy-29-[
18F]fluoro-D-glucose (
18F-FDG) (n=8). Tracer uptake was quantified
using small animal PET/CT. Imaging results were validated by tumor volume changes and gene-expression of Ki67 and TK1.
Top216 (50 mg/kg 0 and 48 hours) inhibited the growth of the A2780 tumor compared to the control group (P,0.001).
18F-
FLT uptake decreased significantly at 2 hours (252%; P,0.001), 6 hours (249%; P=0.002) and Day 1 (247%; P,0.001) after
Top216 treatment. At Day 5
18F-FLT uptake was comparable to uptake in the control group. Uptake of
18F-FLT was
unchanged in the control group during the experiment. In the treatment group, uptake of
18F-FDG was significantly
decreased at 6 hours (221%; P=0.003), Day 1 (229%; P,0.001) and Day 5 (219%; P=0.05) compared to baseline.
Conclusions/Significance: One injection with Top216 initiated a fast and significant decrease in cell-proliferation assessable
by
18F-FLT after 2 hours. The early reductions in tumor cell proliferation preceded changes in tumor size. Our data indicate
that
18F-FLT PET is promising for the early non-invasive assessment of chemotherapy effects in both drug development and
for tailoring therapy in patients.
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Introduction
For the evaluation of effect in animal studies during preclinical
development of new anticancer agents, reduction in tumor volume
is the most commonly used criterion for efficacy. However, the
time until tumor shrinkage can be long and it requires repeated
tumor volume measurements several times weekly to show effect.
Non-invasive molecular imaging such as positron emission
tomography (PET) allows for biological processes to be visualized
and quantified non-invasively over time. A non-invasive method to
detect early biological response following anticancer treatment
would be valuable in anticancer drug development to distinguish
effective from non-effective drugs before changes in tumor volume
become evident.
Increased cell proliferation is one of the main features of cancer
[1]. Much research focuses on the non-invasive visualization of cell
proliferation, which could be used to define a biological response
to treatment early during the course of therapy. 39-deoxy-39-
[
18F]fluorothymidine (
18F-FLT) is used as a PET tracer for
visualization of cell proliferation [2].
18F-FLT is a thymidine
analogue and consequently a substrate of the DNA synthetic
pathway [3]. When taken up in cells
18F-FLT is phosphorylated by
thymidine kinase-1 (TK1), which leads to intracellular trapping.
TK1 activity is tightly cell cycle regulated and is mainly expressed
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12965during the S-phase of the cell cycle; consequently, it is assumed to
reflect the amount of proliferating cells [4,5].
18F-FLT uptake is
positively correlated with cell growth and TK1 activity [5–7].
Several studies have showed a correlation between
18F-FLT
uptake and tumor cell proliferation both in cancer xenografts in
mice [8–11] and human tumor samples [12–14].
Several pre-clinical studies have evaluated proliferation mea-
sured by
18F-FLT PET in response to different chemo- and
radiation therapies in different animal models of cancer [8–11,15–
19]. The results from these studies vary; the first change in
18F-
FLT uptake is found in the range of 24 hours to one week after
initiation of treatment. However, not all studies have found a
correlation between tumor response and a change in
18F-FLT
uptake after start of treatment [20,21]. Seemingly, the time frame
for assessing changes in proliferation is very variable according to
different treatment regimes.
Early non-invasive detection of anti-proliferative activity with
18F-FLT PET could also be useful in a clinical setting to determine
whether patients are responsive to conventional treatment and
during phase I, II and III studies when evaluating responses to new
anti-cancer drugs. Today the most widely used methods to assess
tumor responses clinically is with anatomical imaging techniques
such as computed tomography (CT) and magnetic resonance
imaging (MRI) using the Response Evaluation Criteria In Solid
Tumors (RECIST). However, this often requires several weeks or
months before a possible response becomes evident [22,23].
Recently, guidelines for analyzing tumor responses using PET and
29-deoxy-29-[
18F]fluoro-D-glucose (
18F-FDG) have been suggested
stating the need for additional methods for measuring tumor
responses [24]. New anti-cancer agents are often tumorstatic
rather than tumoricidal and changes in tumor size can be minimal
despite effective treatment thus generating a need for novel
methods for assessing clinical response besides tumor volume
shrinkage.
18F-FDG is currently the most widely used radiotracer for
imaging in oncology and is very useful for detecting and
characterizing cancers. Several studies have analyzed changes in
18F-FDG uptake following anti-cancer treatment, but with
variable results [25].
18F-FDG suffers from the limitation that it
may not detect effects at an very early stage and an inflammatory
response after cancer treatment may to some degree obscure the
detection of anti-cancer effect [26,27].
Top216 is a more potent and metabolically stable derivative of
Top001, which was discovered by BioImage to have potent and
selective killing effect on breast cancer cell lines [28]. Top001
inhibits the mTOR pathway in a cell-selective manner after
prolonged incubation (,24 hours). The correlation between
mTOR inhibition and cell line sensitivity is good but not perfect.
Top216 inhibits protein, RNA, and DNA synthesis in sensitive
cell lines after 1–2 hours of incubation and induces apoptosis.
Induction of apoptosis as measured by caspase 3/7 activity is
detectable after 6 hours in most sensitive cell lines. Top001 and
Top216 do not significantly inhibit kinases (Upstate kinase panel)
or receptors (Cerep panel) at relevant concentrations and at
present the exact target or mode of action remains to be identified.
Top216 shows potent in vivo efficacy in mouse xenograft models of
human breast, prostate, ovarian, and pancreatic cancer, both
when administered i.v. and p.o.. Top216 is currently undergoing
regulatory safety and toxicology examination with the aim to move
the compound into the clinic.
The aim of the study was to use
18F-FLT PET to study
treatment responses to a new anti-cancer compound non-
invasively. To do so we imaged cell proliferation in vivo with
18F-
FLT PET in a human cancer mouse tumor model following
initiation of treatment with Top216. Uptake of
18F-FLT was
compared with uptake of




Animal care and all experimental procedures were performed
under the approval of the Danish Animal Welfare Council (2006/
561-1124). Female NMRI (Naval Medical Research Institute)
nude mice (8–11 weeks old) were acquired from Taconic Europe
(Lille Skensved, Denmark) and allowed to acclimatize for one
week in the animal facility before any intervention was initiated.
The human ovarian carcinoma cell line A2780 (a gift from R.
Ozols, Fox Chase Cancer Center Philadelphia, PA, January 2004)
was used. 10
7 cells in 100 mL medium mixed with 100 mL
Matrixgel
TM Basement Membrane Matrix (BD Biosciences, San
Jose, CA, USA) were injected subcutaneously into the left and
right flank respectively during anesthesia with 1:1 v/v mixture of
HypnormH (Janssen Pharmaceutica, Beerse, Belgium) and
DormicumH (Roche, Basel, Switzerland). The cell line has been
tested free of mycoplasma; however, it has not been authenticat-
ed. Cells were cultured in RPMI (Roswell Park Memorial
Institute) medium 1640+ GlutaMAX (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal calf serum (Biological
Industries, Israel) and 1% penicillin-streptomycin (Invitrogen) in
5% CO2 at 37uC.
Experimental design
Six groups of mice were followed (n=5–10 tumors per group).
Treatment was started at day 12–24 after implantation of tumor
cells, when tumor volumes were on average 225 mm
3. Mice
received Top216 treatment 50 mg/kg i.v. or vehicle (2% DMSO,
20% HP-b-CD in saline) at 0 and 48 hours (figure 1). This dose of
Top216 was in preceding analyses shown to inhibit growth of the
A2780 xenograft tumor (data not shown). Before treatment was
started, the mice were scanned with
18F-FLT or
18F-FDG in order
to determine the baseline level of tracer uptake.
18F-FLT or
18F-
FDG scans were repeated at 6, 30 (Day 1) and 126 (Day 5) hours
after injection of Top216 or vehicle (figure 2) In addition, a group
of mice was scanned with
18F-FLT at baseline and 2 hours after
Figure 1. Chemical structure of Top216.
doi:10.1371/journal.pone.0012965.g001
FLT-PET and Exp. Chemotherapy
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followed by CT during the experiments [29]. Tumor volumes
were calculated relative to volume at baseline.
Expression of Ki67 and TK1 was analyzed in vitro in a parallel
group of mice, which were treated with either Top216 or vehicle
and biopsied before and at 6, 30 (Day 1) and 126 (Day 5) hours
after initiation of treatment. Biopsies were removed with an 18G
needle and placed immediately in RNA laterH (Ambion (Europe)
Limited, Cambridgeshire, UK). All samples were stored at 4uC
and the following day RNAlaterH was removed and samples




[18F]FLT was synthesized using 3-N-Boc-1-[5-O-(4,49-dimethox-
ytrityl)-3-O-nosyl-2-deoxy-b-D-lyxofuranosyl]thymine as precursor
and synthesized on a GE TracerLab MX Synthesizer. All reagents
and FLT cassetteswere purchased from ABX(Radeberg,Germany).
The radiochemical purity was determined after measuring the
content of fluoride-18 and other radioactive impurities in the FLT
solutionmeasuredwithTLCandHPLCrespectively.Thecontentof
ethanol and acetonitrile was determined by GC analysis. The pH
wasmeasuredwithapH-meter.Inseparatepreparationsthestability
of the preparations was examined after 8 hours. HPLC was
performed on a Gilson HPLC system (Biolab A/S, Denmark)
equipped with a Dionex UV-detector (Dionex Denmark A/S,
Denmark) and an in-line radioactivity detector. The HPLC column
was a Luna 5 m C18(2) 100A, 15064.6 mm (Phenomenex,
Denmark). The eluent was water/acetonitrile 90/10 and a flow
rate of 1 ml/min. UV detection at 267 nm. TLC plates were
obtained from Merck and water/acetonitrile 5/95 was used as
eluent. Residual solvents were determined on a Shimatzu GC 2014
(Holm & Halby, A/S, Denmark) equipped with a Chromosorb 101,
100–120 Mesh, 1/806109 column, FID detector and helium carrier
gas. The temperature of the column was 210uC. The radiochemical
purity of
18F-FLT was .98% with a specific radioactivity ranging
from 150–270 GBq/mmol at EOS. The ethanol content was in the
range 7–8% and the amount of acetonitrile was below the detection
limit. The pH was 7.5–7.8. The radiochemical purity, ethanol
content and pH did not change after 8 hours of storage at room
temperature.
18F-FDG was acquired from daily productions for clinical use
(Rigshospitalet, Copenhagen, Denmark).
microPET and microCT imaging
Mice were injected i.v. with 10.061.5 (mean 6 SD) MBq
18F-
FDG or 6.962.4 (mean 6 SD) MBq
18F-FLT. Mice were fasted
overnight before each
18F-FDG scan [30]. One hour after tracer
injection mice were anaesthetized with 3% sevofluran (Abbott
Scandinavia AB, Solna, Sweden) mixed with 35% O2 in N2 and
fixed on a bed in presence of three fiducial markers allowing fusion
of PET and CT pictures. A 20 min PET scan was acquired using a
MicroPET Focus 120 (Siemens Medical Solutions, Malvern, PA,
USA). After data acquisition, PET data were arranged into
sinograms and subsequently reconstructed with the maximum a
posteriori (MAP) reconstruction algorithm. The pixel size was
0.86660.86660.796 mm and in the center field of view the
resolution was 1.4 mm full-width-at-half-maximum.
Following the microPET scan, a microCT scan was acquired
with a MicroCATH II system (Siemens Medical Solutions). A 7
minute and 10 seconds CT scan was performed with parameter
settings: 360 rotation steps, tube voltage 60 kV, tube current
500 mA, binning 4 and exposure time 310 ms. The pixel size was
0.09160.09160.091 mm.
PET and microCT images were fused in the Inveon software
(Siemens Medical Solutions). Before fusion region of interests
(ROIs) were drawn on the CT pictures manually by qualitative
assessment covering the whole tumors and subsequently tumor
volume and tracer uptake, assessed by standard uptake values
(SUV) mean and maximum, were generated by summation of
voxels within the tomographic planes.
Quantitative real-time polymerase chain reaction (qPCR)
Total RNA was isolated from the biopsies with TRI reagentH
following the manufacturer’s instructions (Molecular Research
Center Inc., OH, USA) and subsequently RNA integrity was
measured on a 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). RNA quality is stated as RNA integrity number
(RIN) [31]. The concentration of the RNA was determined by
NanoDrop 1000 (Thermo Fisher Scientific, Wilmington, DE,
USA). Total RNA (0.3 mg) was reversed transcribed using the
Affinityscript
TM QPCR cDNA Synthesis kit (Stratagene, La Jolla,
CA, USA) according to the manufacturer’s instructions. Samples
were cooled down and stored at 220uC until further use.
Gene expression was quantified on the Mx3000PH real-time
PCR system from Stratagene. Ki67 and TK1 were each quantified
Figure 2. Schematic view of the experimental design.
doi:10.1371/journal.pone.0012965.g002
FLT-PET and Exp. Chemotherapy
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QPCR Core Reagent Kit (Stratagene) was used. Optimization of
assays resulted in 50% increase in dNTP and Taq polymerase. An
MgCl concentration of 5.5 mM was used for all experiments. The
following thermal profile was used in all experiments: 10 minutes
of denaturation at 95uC followed by 45 cycles with denaturation
for 30 seconds at 95uC and annealing/elongation at 60uC for 1
minutes.
Relative quantification by the comparative method (2
2DDCt)
[32] was used. The measurements were corrected for the efficiency
of the PCR reaction calculated by 5-fold dilution curves thereby
replacing 2 in the formula with (E+1) [33]. Efficiency corrections
were made for each gene in every assay. Tissue from baseline
samples served as calibrator. TBP was used as reference gene. This
gene was previously tested to be stable in tumor versus normal
tissue and subsequently found to be stable in this experimental
setup.
Primers and TaqMan dual-labeled probes were designed using
Beacon Designer (PREMIER Biosoft, Palo Alto, CA USA).
Primers and probes are shown in (table 1). For each gene the
optimal primer and probe concentration was found. All samples
were run in triplicate using one ml of cDNA. To each sample a no-
reverse transcription control (NoRT) was included, and on each
plate a no-template control (NTC) was included.
Statistical analysis
Comparison of tumor volume between Top216 treated and
control groups were calculated using a unpaired student’s t-test.
Paired t-test was used for intra-group comparisons. Bonferroni
correction of p-values for multiple comparisons was applied. All
data were tested to be normal distributed by means of
Kolmogorov-Smirnov test. Calculations were made in SPSS
16.0. Data are reported as mean 6 SEM and P,0.05 was
considered statistically significant.
Results
Effect of Top216 on tumor size
Top216 (50 mg/kg at 0 and 48 hours) inhibited the growth of
A2780 human ovary cancer xenografts in mice in vivo compared
with the control group (P,0.001) (figure 3). The sizes of the
untreated tumors increased by approximately a factor 3 during the
study and volumes of the treated tumors were unchanged.
18F-FLT and
18F-FDG uptake
Baseline tumor uptake of
18F-FLT in the A2780 tumor model
was relatively high (SUVmean 1.0560.03), making it easy to
differentiate tumor from non-tumor tissues whereas for
18F-FDG
only a modest tumor uptake was observed (SUVmean 0.4860.02).
In the control group, baseline
18F-FLT uptake predicted tumor
volume increase over 5 days (linear regression of SUVmean
baseline vs. tumor volume ratio Day 5/baseline: r
2=0.61,
P=0.04) (figure 3). No correlation between baseline
18F-FDG
uptake and tumor volume increase was observed.
Uptake of
18F-FLT assessed by SUVmean decreased signifi-
cantly from 1.0960.03 at baseline to 0.5360.02 (252%;
P,0.001) at 2 hours, to 0.5660.06 (249%; P,0.001) at 6 hours
and to 0.5860.03 (247%; P,0.001) at Day 1 after Top216
treatment initiation (figure 4+5).
After 5 days
18F-FLT uptake (1.3360.08) was comparable to
baseline uptake. SUVmean was unchanged in the control group
during the experiment. SUVmax values decreased significantly
from 2.0160.09 at baseline to 0.8960.05 at 2 hours (255%;
P,0.001), to 0.9460.08 at 6 hours (253%; P=0.002) and to
0.8460.03 at Day 1 (258%; P,0.001). SUVmax values increased
to 2.2660.12 at Day 5 after treatment initiation (13%; P=0.04).
SUVmax was unchanged in the control group, however increased
slightly at Day 5 after treatment initiation compared to baseline
(13%; P=0.03).
Uptake of
18F-FDG assessed by SUVmean decreased significant
from 0.4960.03 at baseline to 0.3960.02 (221%; P=0.003) at
6 hours, to 0.3560.01 (229%; P,0.001) at Day 1 and to
0.4060.02 (219%; P=0.05) at Day 5 (figure 4+5). Uptake of
18F-
FDG in the control group was significantly increased at Day 5
compared to baseline uptake (27%; P=0.05). SUVmax values
decreased significantly from 0.9260.06 at baseline to 0.6460.04
at 6 hours post injection (231%; P,0.001), to 0.5360.02 at Day
1( 242%; P,0.001) and to 0.6660.03 at Day 5 (229%; P=0.01).
SUVmax was unchanged in the control group during the
experiment.
Expression of Ki67 and TK1
Expression of the reference gene TBP was constant throughout
the experiment. Differences in Ct-values between normal samples
and NoRT samples were 13 (median). RNA integrity numbers
(RIN-values) were 9.160.1 (mean6SD) for all samples.
Gene expression levels of Ki67 and TK1 are shown in figure 6.
In the treatment group expression of Ki67 was significantly lower
at 6 hours post injection (231%, P=0.01) and Day 1 (271%;
P,0.001) after treatment start compared to baseline. Expression
of Ki67 was 21% increased at Day 5 (P=0.04) compared to
baseline. Expression of Ki67 in the control group was significantly
lower at 6 hours (217%; P=0.01) compared to baseline.
In the treatment group expression of TK1 was significantly
decreased at Day 1 (256%, P,0.001) compared to baseline. At
Day 5 expression of TK1 was increased (30%, P=0.013)
compared to baseline. In the control group expression of TK1
was unchanged during the experiment.
Discussion
One injection with Top216 initiated a fast and significant
decrease in cell proliferation of 52% assessable by
18F-FLT PET as
early as 2 hours post-injection. This decrease lasted for at least 1
Table 1. Primer and probe sequences for the genes investigated.
Gene Forward primer (59-39) Reverse primer (59-39)5 9 fluorophore Probe (59-39)3 9 Quencher
Amplicon
length (bp)
TBP tgttgagttgcagggtgtgg tagcagcacggtatgagcaac HEX tgcccttctgtaagtgcccaccgc BHQ-1 133
Ki67 tcccgcctgttttctttctgac ctctccaaggatgatgatgctttac FAM agcccgatgccacccagtacagga BHQ-1 121
TK1 gccgatgttctcaggaaaaagc gcgagtgtctttggcatacttg FAM cgtccgtcgcttccagattgctca BHQ-1 103
doi:10.1371/journal.pone.0012965.t001
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PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12965Figure 3. Tumor growth. A) The effects of Top216 on the growth of A2780 tumor xenografts. Tumor volume was determined by microCT. Mice
were treated with Top216 (50 mg/kg) or vehicle at 0 and 48 hours. *) P,0.05, **) P,0.01 vs. baseline and
### )P ,0.001 vs. control. n=15 tumors




Figure 4. Fused PET/CT images. A) The eight images at left are representative coronal fused PET/CT images of two mice scanned with
18F-FLT at
baseline and at 6 hours and 1 and 5 days after treatment start. The images at the top show one mouse treated with Top216 and the images at the
bottom show one control mouse which received vehicle. The four images at right show fused PET/CT pictures of two representative mice treated
with either Top216 or vehicle and scanned at baseline and 2 hours after treatment initiation. The arrows point towards the tumors. B) Representative
coronal fused PET/CT images of two mice scanned with
18F-FDG at baseline and 6 hours and 1 and 5 days after treatment start. The images at the top
show one mouse treated with Top216 and the images at the bottom show one control mouse which received vehicle. The arrows point towards the
tumors.
doi:10.1371/journal.pone.0012965.g004
FLT-PET and Exp. Chemotherapy
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nd treatment) uptake of
18F-
FLT was comparable to uptake in the control group suggesting
that the tumor cells had regained their proliferation capacity.
Uptake of
18F-FLT in the control group did not change during the
experiment thus validating the anti-proliferative effect of Top216.
In contrast to the steep decrease in
18F-FLT uptake following
treatment start, a small, but significant, decrease in
18F-FDG
uptake was observed at 6 hours and on Day 1 after initiation of
Top216 treatment, and this decrease lasted until Day 5. Changes
in
18F-FLT uptake (max decrease: 52%; 2 h) were more
pronounced than changes in
18F-FDG uptake (max decrease:
29%; Day 1). However, at the end of the experiment,
18F-FDG
uptake remained lower than at baseline in the Top216 group,
whereas it was increased in the control group.
The decrease in
18F-FLT uptake early post-injection was not
accompanied by a decrease in tumor volume as volume of the
tumors did not change during the course of therapy. This
illustrates that the use of non-invasive imaging to assess tumor
response is important since evaluating reduction in tumor volume
as an endpoint would have generated a false negative conclusion.
Anti-volume effect of Top216 was, however, still seen compared
with the control group. Changes in tracer availability e.g. as a
consequence of tumor perfusion alterations after treatment, could
account for some of the effect on decreased
18F-FLT uptake.
However, the fact that
18F-FDG uptake did not decrease the same
way as
18F-FLT leads to the assumption that decrease in
18F-FLT
uptake is not only due to a change in tumor perfusion but also to a
physiologic change in tumor cell proliferation. This was further
validated by a similar decrease in Ki67 gene expression.
The measurements of tracer uptake on Day 5 can be interpreted
both as a measure of cell proliferation 5 days after treatment
initiation and as proliferation status 3 days after the second
injection of Top216. Consequently, one injection of Top216
inhibited proliferation somewhere between 1 and 3 days,
thereafter the tumor cells recovered their proliferation capacity.
This information could be useful when planning treatment
schedules during pre-clinical investigations and in future clinical
protocols in order to find the optimal treatment schedule.
On Day 5 after treatment initiation
18F-FDG uptake was 19%




18F-FDG uptake assessed by SUVmean and SUVmax at baseline and following treatment with Top216.
Top216/vehicle treatment was initiated at 0 hours and repeated at 48 hours after the first injection. N=5–10 tumors per group. *) P,0.05, **)
P,0.01, ***) P,0.001 compared to baseline. The two graphs at left show data from the
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18F-FDGwasconsequentlyaffectedfor
al o n g e rt i m et h a n
18F-FLT uptake. This indicates that even though
cell proliferation after 5 days (3 days after the 2
nd treatment) was
comparable to baseline, biological effects of the treatment still existed
and were visualized by
18F-FDG. Uptake of
18F-FDG was
significantly lower at 6 hours after start of treatment compared to
baseline uptake. However the decrease of 21% from an already low
uptake is not easily visualized on the PET/CT images (figure 4).
Our findings that
18F-FLT was superior to
18F-FDG for
assessing the early responses following anti-cancer treatment are
in agreement with other studies [8,11,21]. Baseline levels of
18F-
FDG uptake in the tumor model were low and only about half of
the baseline levels of
18F-FLT uptake which is in agreement with
the findings of others [11,17]. However, other studies have found a
higher
18F-FDG uptake in several xenograft models compared to
18F-FLT uptake [16,19,21]. It has previously been shown that it is
more difficult to measure treatment response in tumors with low
baseline tracer uptake, which is in concordance with the results
found in this study [11,21,34].
The findings from other studies using
18F-FLT PET to assess
early responses to anti-cancer treatment have been very variable,
where response to a histone deacetylase inhibitor was observed
after 4 days [10], response to cisplatin is seen after 1 day [9],
response to cyclophosphamide and mTOR inhibition is evident
after 2 days [16] and the ErbB kinase inhibitor initiated a decrease
in
18F-FLT uptake 2 days after treatment initiation whereas no
response was observed at 6 and 24 hours [11]. However
comparison of the studies is difficult due to different treatment
and scanning schedules and variable tumor models. Compared to
other studies we found a steep decrease in
18F-FLT uptake assessed
by PET and this decrease was observed much earlier (2 and
6 hours). It remains to be established whether this early response is
compound specific or simply due to our protocol being the first to
assess response so early after treatment.
Whether or not the early change in
18F-FLT and
18F-FDG can
be a predictor of clinical outcome is still unknown and further
studies investigating early changes and overall survival are needed
in order to answer that question.
Figure 6. Expression of Ki67 and TK1 normalized to expression of reference gene TBP. Data are presented as fold changes following
treatment with Top216/vehicle relative to baseline levels (n=7 tumors per group). Top216 treatment was initiated at 0 hours and repeated at
48 hours after the first injection. *) P,0.05, **) P,0.01, ***) P,0.001 compared to baseline.
doi:10.1371/journal.pone.0012965.g006
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18F-FLT uptake and Ki67 gene expression
showed a similar change following treatment with Top216.
However, Ki67 mRNA levels did not decrease as much as
18F-
FLT uptake 6 hours after treatment initiation. A possible
explanation could be that changes in enzymatic activity occur
before changes in mRNA levels. The correlation between Ki67
gene expression and
18F-FLT uptake in our study is in accordance
with other studies finding strong correlation between Ki67 at the
protein level and
18F-FLT uptake [8–11]. We found a significant
decrease in
18F-FLT uptake as early as 2 and 6 hours after
treatment initiation; however, despite a significantly lower
18F-
FLT uptake at 6 hours, a decrease in TK1 gene expression was
first evident on Day 1 after treatment initiation. TK1 enzyme
activity is positively correlated with
18F-FLT uptake [6,7] and it
has been shown that transcriptional mechanisms may take part in
regulation of TK1 activity where both TK1 protein and mRNA
levels were related to a decrease in
18F-FLT uptake following
treatment with a histone deacetylase inhibitor [10]. Early changes
in
18F-FLT uptake without changes in TK1 mRNA levels are
likely due to changes in protein levels, posttranslational protein
modifications or changes in ATP levels [7,10,35]. ATP is required
for TK1 activity [36] and other studies have similarly found a
decreased
18F-FLT uptake, despite a high TK1 level, which could
be explained by a low level of ATP [8].
In conclusion, we found a 52% decrease in
18F-FLT uptake as
early as 2 hours after the first injection of Top216.
18F-FLT was
superior to
18F-FDG as a noninvasive tool to assess early biological
responses to Top216. Decrease in
18F-FLT uptake preceded
reductions in tumor growth. The results from this study show the
possibility of using non-invasive
18F-FLT PET to evaluate
responses during development of new anti-cancer agents and of
following treatments without the need to acquire serial tumor
biopsies or waiting weeks or months before a possible tumor
reduction is seen.
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